Current partner codePEPTIDESDE
NCT03279419·Not applicable·OBSERVATIONAL

Thermal Imaging in Liver Disease.

Status

Completed

Phase

Not applicable

Enrollment

66

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

This is a feasibility study, to assess if thermal imaging and/or near infrared imaging will be useful in identifying changes in the peripheral circulation in patients with different stages of liver disease. The aim of this study is to use new and advanced thermal imaging techniques to identify changes in the peripheral circulation and hand temperature in patients with liver disease. These changes could be used as a non-invasive marker of the severity and progression of liver disease. Thermal imaging will also be used to assess the changes in the peripheral vasculature with the use of terlipressin, a drug used as treatment for specific complications of liver disease. Patients with acute or chronic liver disease from any aetiology will be recruited, along with patients without liver disease as healthy controls. Patients with disease or on drugs known to affect the peripheral vasculature will be excluded. All studies will be performed in a ward setting in the Royal Infirmary of Edinburgh. The subjects will be required for up to three sessions, each lasting 30 minutes. The session will involve static thermal images being taken, and video images of the hands warming up after being cooled for 30 seconds in water at a temperature of 7 degrees Celsius. If the patient is receiving terlipressin therapy, static images will be taken before, during and after terlipressin therapy.

Interventions

Treatment arms and agents.

DIAGNOSTIC_TEST

Thermal imaging

Use of thermal imaging camera to capture images of peripheral vasculature (hands).

Timeline

From registration to results.

  1. First posted

    Sep 12, 2017

  2. Study start

    Sep 1, 2019

  3. Primary completion

    Sep 1, 2019

  4. Study completion

    Dec 1, 2019

  5. Results posted

    Not reported

  6. Registry updated

    Jun 18, 2024

Outcomes

What the study measures.

Primary outcomes

Changes in peripheral vasculature as assessed by thermal imaging

Time frame · 2 years

Secondary outcomes

Changes in peripheral vasculature in response to terlipressin therapy.

Time frame · 2 years

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
70 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: * diagnosis of chronic liver disease (any stage) * diagnosis of acute liver disease (any aetiology) Exclusion Criteria: * on drugs known to affect peripheral circulation * conditions known to affect peripheral circulation e.g. Raynauds

Study locations

1 registered sites.

United Kingdom. Showing up to 24 locations stored in the fast local snapshot.

Univerity of Edinburgh and NHS Lothian

Edinburgh, United Kingdom

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Terlipressin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.